» Articles » PMID: 11157913

New Approach for Accurate Simulation of Human Pharmacokinetics in an in Vitro Pharmacodynamic Model: Application to Ciprofloxacin

Overview
Date 2001 Feb 7
PMID 11157913
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

An in vitro pharmacodynamic model using a disposable dialyser unit and computer-controlled devices was developed. Feedback control of peristaltic pump flow rates is used to maintain constant flow rates, thus avoiding the problem of the modification of the physical properties of the tubing that generally occurs. Fast equilibrium is obtained with capillaries, which allows simulation of the same kinetic profile in the central and the peripheral compartments. Thus, more accurate simulation of plasma, extracapillary fluid or whole tissue kinetics can be performed. Our model was validated by simulation of a 30 min infusion of a 200 mg dose, and of an oral administration of a 500 mg dose of ciprofloxacin.

Citing Articles

Recovery rates of combination antibiotic therapy using microdialysis simulating conditions.

Dhanani J, Parker S, Lipman J, Wallis S, Cohen J, Fraser J J Pharm Anal. 2019; 8(6):407-412.

PMID: 30595948 PMC: 6308031. DOI: 10.1016/j.jpha.2018.07.003.


In vitro simulation of in vivo pharmacokinetic model with intravenous administration via flow rate modulation.

Chen Y, Liang W, Hu J, He G, Wu X, Liu X J Pharmacokinet Pharmacodyn. 2014; 42(1):33-43.

PMID: 25354895 DOI: 10.1007/s10928-014-9396-7.


Activity of linezolid in an in vitro pharmacokinetic-pharmacodynamic model using different dosages and Staphylococcus aureus and Enterococcus faecalis strains with and without a hypermutator phenotype.

Ba B, Arpin C, Bikie Bi Nso B, Dubois V, Saux M, Quentin C Antimicrob Agents Chemother. 2010; 54(4):1443-52.

PMID: 20100878 PMC: 2849367. DOI: 10.1128/AAC.01022-09.


Activity of gatifloxacin in an in vitro pharmacokinetic-pharmacodynamic model against Staphylococcus aureus strains either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin resistance.

Ba B, Arpin C, Vidaillac C, Chausse A, Saux M, Quentin C Antimicrob Agents Chemother. 2006; 50(6):1931-6.

PMID: 16723548 PMC: 1479150. DOI: 10.1128/AAC.01586-05.


Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model.

Ba B, Feghali H, Arpin C, Saux M, Quentin C Antimicrob Agents Chemother. 2004; 48(3):946-53.

PMID: 14982788 PMC: 353051. DOI: 10.1128/AAC.48.3.946-953.2004.